Design of a single AAV vector for coexpression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of parkinson's disease

Molecular Therapy

Volumn 20, Issue 7, 2012, Pages 1315-1326

  Cederfjäll, Erik ^a   Sahin, Gurdal ^a   Kirik, Deniz ^a   Björklund, Tomas ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CELL DNA; DOPA; GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE I; PARVOVIRUS VECTOR; TYROSINE 3 MONOOXYGENASE;

AMINO ACID SYNTHESIS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN CORTEX; BRAIN REGION; CELL LEVEL; CONFERENCE PAPER; CONTROLLED STUDY; CONVALESCENCE; CORPUS STRIATUM; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FUNCTIONAL ASSESSMENT; GENE EXPRESSION SYSTEM; GENETIC TRANSDUCTION; GLOBUS PALLIDUS; HISTOPATHOLOGY; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; RAT; VIRAL GENE DELIVERY SYSTEM;

ANIMALIA; RATTUS;

EID: 84863494448     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.1     Document Type: Article

References (52)

1. Carlsson, A, Lindqvist, M and Magnusson, T (1957). 3,4- Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature 180: 1200.
2. Cotzias, GC, Van Woert, MH and Schiffer, LM (1967). Aromatic amino acids and modification of parkinsonism. N Engl J Med 276: 374-379.
3. Mouradian, MM, Juncos, JL, Fabbrini, G and Chase, TN (1987). Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Ann Neurol 22: 475-479. (Pubitemid 17164770)
4. Obeso, JA, Olanow, CW and Nutt, JG (2000). Levodopa motor complications in Parkinson's disease. Trends Neurosci 23(10 Suppl): S2-S7.
5. Olanow, CW, Obeso, JA and Stocchi, F (2006). Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 5: 677-687. (Pubitemid 44081890)
6. Bencsics, C, Wachtel, SR, Milstien, S, Hatakeyama, K, Becker, JB and Kang, UJ (1996). Double transduction with GTP cyclohydrolase I and tyrosine hydroxylase is necessary for spontaneous synthesis of L-DOPA by primary fibroblasts. J Neurosci 16: 4449-4456. (Pubitemid 26243040)
7. Hökfelt, T, Fuxe, K and Goldstein, M (1973). Immunohistochemical localization of aromatic L-amino acid decarboxylase (DOPA decarboxylase) in central dopamine and 5-hydroxytryptamine nerve cell bodies of the rat. Brain Res 53: 175-180.
8. Kirik, D, Georgievska, B, Burger, C, Winkler, C, Muzyczka, N, Mandel, RJ et al. (2002). Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc Natl Acad Sci USA 99: 4708-4713. (Pubitemid 34286049)
9. Shen, Y, Muramatsu, SI, Ikeguchi, K, Fujimoto, KI, Fan, DS, Ogawa, M et al. (2000). Triple transduction with adeno-associated virus vectors expressing tyrosine hydroxylase, aromatic-L-amino-acid decarboxylase, and GTP cyclohydrolase I for gene therapy of Parkinson's disease. Hum Gene Ther 11: 1509-1519. (Pubitemid 30670603)
10. Azzouz, M, Martin-Rendon, E, Barber, RD, Mitrophanous, KA, Carter, EE, Rohll, JB et al. (2002). Multicistronic lentiviral vector-mediated striatal gene transfer of aromatic L-amino acid decarboxylase, tyrosine hydroxylase, and GTP cyclohydrolase I induces sustained transgene expression, dopamine production, and functional improvement in a rat model of Parkinson's disease. J Neurosci 22: 10302-10312. (Pubitemid 35416868)
11. Mandel, RJ, Rendahl, KG, Spratt, SK, Snyder, RO, Cohen, LK and Leff, SE (1998). Characterization of intrastriatal recombinant adeno-associated virus-mediated gene transfer of human tyrosine hydroxylase and human GTP-cyclohydrolase I in a rat model of Parkinson's disease. J Neurosci 18: 4271-4284. (Pubitemid 28243820)
12. Björklund, T, Carlsson, T, Cederfjäll, EA, Carta, M and Kirik, D (2010). Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease. Brain 133(Pt 2): 496-511.
13. Björklund, T, Hall, H, Breysse, N, Soneson, C, Carlsson, T, Mandel, RJ et al. (2009). Optimization of continuous in vivo DOPA production and studies on ectopic DA synthesis using rAAV5 vectors in Parkinsonian rats. J Neurochem 111: 355-367.
14. Leff, SE, Rendahl, KG, Spratt, SK, Kang, UJ and Mandel, RJ (1998). In vivo L-DOPA production by genetically modified primary rat fibroblast or 9L gliosarcoma cell grafts via coexpression of GTP cyclohydrolase I with tyrosine hydroxylase. Exp Neurol 151: 249-264. (Pubitemid 28285906)
15. Hossain, MA, Masserano, JM and Weiner, N (1992). Comparative effects of electroconvulsive shock and haloperidol on in vivo tyrosine hydroxylation and tetrahydrobiopterin in the brain of rats with 6-hydroxydopamine lesions. Brain Res 598: 121-126. (Pubitemid 23013052)
16. Amendola, M, Venneri, MA, Biffi, A, Vigna, E and Naldini, L (2005). Coordinate dual-gene transgenesis by lentiviral vectors carrying synthetic bidirectional promoters. Nat Biotechnol 23: 108-116. (Pubitemid 41724633)
17. Marks, WJ Jr, Ostrem, JL, Verhagen, L, Starr, PA, Larson, PS, Bakay, RA et al. (2008). Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol 7: 400-408.
18. Kaplitt, MG, Feigin, A, Tang, C, Fitzsimons, HL, Mattis, P, Lawlor, PA et al. (2007). Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet 369: 2097-2105. (Pubitemid 46935946)
19. Eberling, JL, Jagust, WJ, Christine, CW, Starr, P, Larson, P, Bankiewicz, KS et al. (2008). Results from a phase I safety trial of hAADC gene therapy for Parkinson disease. Neurology 70: 1980-1983.
20. Jarraya, B, Boulet, S, Ralph, GS, Jan, C, Bonvento, G, Azzouz, M et al. (2009). Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci Transl Med 1: 2ra4.
21. Schoch, S, Cibelli, G and Thiel, G (1996). Neuron-specific gene expression of synapsin I. Major role of a negative regulatory mechanism. J Biol Chem 271: 3317-3323. (Pubitemid 26055638)
22. Zufferey, R, Donello, JE, Trono, D and Hope, TJ (1999). Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors. J Virol 73: 2886-2892. (Pubitemid 29135675)
23. Dodiya, HB, Bjorklund, T, Stansell, J 3rd, Mandel, RJ, Kirik, D and Kordower, JH (2010). Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther 18: 579-587.
24. Reimsnider, S, Manfredsson, FP, Muzyczka, N and Mandel, RJ (2007). Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Mol Ther 15: 1504-1511. (Pubitemid 47103062)
25. Corti, O, Sánchez-Capelo, A, Colin, P, Hanoun, N, Hamon, M and Mallet, J (1999). Long-term doxycycline-controlled expression of human tyrosine hydroxylase after direct adenovirus-mediated gene transfer to a rat model of Parkinson's disease. Proc Natl Acad Sci USA 96: 12120-12125. (Pubitemid 29502868)
26. Beeler, JA, Cao, ZF, Kheirbek, MA, Ding, Y, Koranda, J, Murakami, M et al. (2010). Dopamine-dependent motor learning: insight into levodopa's long-duration response. Ann Neurol 67: 639-647.
27. Nevalainen, N, Af Bjerkén, S, Lundblad, M, Gerhardt, GA and Strömberg, I (2011). Dopamine release from serotonergic nerve fibers is reduced in L-DOPA-induced dyskinesia. J Neurochem 118: 12-23.
28. Cederfjäll, E, Sahin, G and Kirik, D (2011). Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain. Neurobiol Dis (epub ahead of print).
29. Mouradian, MM, Juncos, JL, Fabbrini, G and Chase, TN (1987). Motor fluctuations in Parkinson's disease: pathogenetic and therapeutic studies. Annals of Neurology 22: 475-479. (Pubitemid 17164770)
30. Lloyd, K and Hornykiewicz, O (1970). Parkinson's disease: activity of L-dopa decarboxylase in discrete brain regions. Science 170: 1212-1213.
31. Nagatsu, T, Yamamoto, T and Kato, T (1979). A new and highly sensitive voltammetric assay for aromatic L-amino acid decarboxylase activity by highperformance liquid chromatography. Anal Biochem 100: 160-165. (Pubitemid 10157646)
32. Bankiewicz, KS, Eberling, JL, Kohutnicka, M, Jagust, W, Pivirotto, P, Bringas, J et al. (2000). Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using prodrug approach. Exp Neurol 164: 2-14. (Pubitemid 30490717)
33. Alexander, T, Sortwell, CE, Sladek, CD, Roth, RH and Steece-Collier, K (1997). Comparison of neurotoxicity following repeated administration of l-dopa, d-dopa and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fisher 344 and Sprague-Dawley donors. Cell Transplant 6: 309-315. (Pubitemid 27225181)
34. Chen, L, Ding, Y, Cagniard, B, Van Laar, AD, Mortimer, A, Chi, W et al. (2008). Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci 28: 425-433.
35. Watson, C and Paxinos, G. (1986). The Rat Brain in Stereotaxic Coordinates. Academic Press: San Diego, CA.
36. Ungerstedt, U and Arbuthnott, GW (1970). Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. Brain Res 24: 485-493.
37. Carta, M, Carlsson, T, Kirik, D and Björklund, A (2007). Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain 130(Pt 7): 1819-1833. (Pubitemid 47343795)
38. Zanta-Boussif, MA, Charrier, S, Brice-Ouzet, A, Martin, S, Opolon, P, Thrasher, AJ et al. (2009). Validation of a mutated PRE sequence allowing high and sustained transgene expression while abrogating WHV-X protein synthesis: application to the gene therapy of WAS. Gene Ther 16: 605-619.
39. Ulusoy, A, Sahin, G, Björklund, T, Aebischer, P and Kirik, D (2009). Dose optimization for long-term rAAV-mediated RNA interference in the nigrostriatal projection neurons. Mol Ther 17: 1574-1584.
40. Zolotukhin, S, Potter, M, Zolotukhin, I, Sakai, Y, Loiler, S, Fraites, TJ Jr et al. (2002). Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28: 158-167. (Pubitemid 35341079)
41. Zolotukhin, S, Byrne, BJ, Mason, E, Zolotukhin, I, Potter, M, Chesnut, K et al. (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther 6: 973-985. (Pubitemid 29295202)
42. Kirik, D, Georgievska, B, Rosenblad, C and Björklund, A (2001). Delayed infusion of GDNF promotes recovery of motor function in the partial lesion model of Parkinson's disease. Eur J Neurosci 13: 1589-1599. (Pubitemid 32423344)
43. Schallert, T and Tillerson, J. Intervention Strategies for Degeneration of Dopamine Neurons in Parkinsonism: Optimising Behavioral Assessment of Outcome. pp. 131-151 (1999).
44. Schallert, T, De Ryck, M, Whishaw, IQ, Ramirez, VD and Teitelbaum, P (1979). Excessive bracing reactions and their control by atropine and L-DOPA in an animal analog of Parkinsonism. Exp Neurol 64: 33-43. (Pubitemid 9185685)
45. Olsson, M, Nikkhah, G, Bentlage, C and Björklund, A (1995). Forelimb akinesia in the rat Parkinson model: differential effects of dopamine agonists and nigral transplants as assessed by a new stepping test. J Neurosci 15(5 Pt 2): 3863-3875.
46. Montoya, CP, Campbell-Hope, LJ, Pemberton, KD and Dunnett, SB (1991). The "staircase test": a measure of independent forelimb reaching and grasping abilities in rats. J Neurosci Methods 36: 219-228.
47. Winkler, C, Kirik, D, Björklund, A and Dunnett, SB (2000). Transplantation in the rat model of Parkinson's disease: ectopic versus homotopic graft placement. Prog Brain Res 127: 233-265. (Pubitemid 35469064)
48. Dowd, E, Monville, C, Torres, EM and Dunnett, SB (2005). The Corridor Task: a simple test of lateralised response selection sensitive to unilateral dopamine deafferentation and graft-derived dopamine replacement in the striatum. Brain Res Bull 68: 24-30. (Pubitemid 41698873)
49. Romero-Ramos, M, Venero, JL, Cano, J and Machado, A (2000). Low selenium diet induces tyrosine hydroxylase enzyme in nigrostriatal system of the rat. Brain Res Mol Brain Res 84: 7-16.
50. Howells, DW and Hyland, K (1987). Direct analysis of tetrahydrobiopterin in cerebrospinal fluid by high-performance liquid chromatography with redox electrochemistry: prevention of autoxidation during storage and analysis. Clin Chim Acta 167: 23-30. (Pubitemid 17147605)
51. Nagatsu, T, Yamamoto, T and Kato, T. (1979). A new and highly sensitive voltammetric assay for aromatic L-amino acid decarboxylase activity by highperformance liquid chromatography. Anal Biochem 100: 160-165. (Pubitemid 10157646)
52. Thorré, K, Pravda, M, Sarre, S, Ebinger, G and Michotte, Y (1997). New antioxidant mixture for long term stability of serotonin, dopamine and their metabolites in automated microbore liquid chromatography with dual electrochemical detection. J Chromatogr B Biomed Sci Appl 694: 297-303. (Pubitemid 27289502)